| Previous close | 0.1400 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 145.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0800 - 0.1400 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
BloombergModerna’s mRNA Dreams Meet Reality With First Post-Covid Shot
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackStormy Daniels Will Return to Court in Test of Trump’s
Investor's Business DailyIs Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?
Barrons.comLargest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
